ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.862,06
-0,11%
S&P 500
5.741,21
-0,07%
US Dollar vs BRL
5,433
-0,10%
Bitcoin
65.776,59
0,91%
Brent Oil
71,055
0,15%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Akili Inc (AKLI)

  7. Akili Inc (AKLI) Notícias

AKLI

Akili (AKLI)

Akili Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AKLI
DataHoraFonteTítuloCódigoCompanhia
18/06/202417:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKLIAkili Inc
18/06/202417:01Business WireAkili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video GameNASDAQ:AKLIAkili Inc
03/06/202418:21Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:AKLIAkili Inc
29/05/202418:32Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:AKLIAkili Inc
29/05/202417:05Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:AKLIAkili Inc
29/05/202409:00Business WireVirtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health CompanyNASDAQ:AKLIAkili Inc
14/05/202417:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKLIAkili Inc
14/05/202417:01Business WireAkili Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AKLIAkili Inc
06/05/202418:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKLIAkili Inc
30/04/202409:00Business WireAkili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial ResultsNASDAQ:AKLIAkili Inc
06/03/202418:28Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AKLIAkili Inc
06/03/202418:11Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AKLIAkili Inc
06/03/202418:07Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AKLIAkili Inc
29/02/202418:01Business WireAkili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AKLIAkili Inc
27/02/202404:00Business WirePureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in JapanNASDAQ:AKLIAkili Inc
26/02/202410:47Business WireAkili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in JapanNASDAQ:AKLIAkili Inc
23/02/202419:28Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKLIAkili Inc
23/02/202409:57Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AKLIAkili Inc
21/02/202418:05Business WireAkili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance UpdatesNASDAQ:AKLIAkili Inc
18/12/202310:00Business WireEndeavorRxⓇ, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17NASDAQ:AKLIAkili Inc
09/11/202318:02Business WireAkili Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AKLIAkili Inc
19/10/202313:27Business WireAkili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ETNASDAQ:AKLIAkili Inc
12/10/202309:00Business WireEmployees with ADHD Aren’t Reaching Their Full Potential at Work, Akili Study FindsNASDAQ:AKLIAkili Inc
06/10/202308:00Business WireAkili Announces Leadership TransitionNASDAQ:AKLIAkili Inc
27/09/202308:45Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AKLIAkili Inc
21/09/202309:00Business WireAkili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHDNASDAQ:AKLIAkili Inc
13/09/202309:11Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AKLIAkili Inc
13/09/202309:00Business WireAkili Announces Business Transformation, Focusing on Non-prescription ModelNASDAQ:AKLIAkili Inc
10/08/202317:01Business WireAkili Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AKLIAkili Inc
10/07/202308:00Business WireAkili to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10 at 4:30 p.m. ETNASDAQ:AKLIAkili Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AKLI

Seu Histórico Recente

LSE
62TH
Cred Ag Co 31
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados